<DOC>
	<DOCNO>NCT00498680</DOCNO>
	<brief_summary>A prospective , randomize , 3-arm parallel trial 45 male ED never expose PDE5i therapy ( naïve patient ) enrolled.In group , every patient receive three treatment regime ( Viagra®50mg &amp; Levitra®10mg , Viagra®100mg , Levitra®20mg ) , different sequence administration manner eventually patient receive regime double- blind fasion.Safety evaluate pre- screening measure hourly vital sign ( blood pressure , heart rate ) 4 consecutive hour take half-dose combination . Any decrease blood pressure 20 mmhg baseline exclude subject study . Effcacy evaluate questionnaire ( IIEF , Quality erection questionnaire , grade erection scale , Sear , QVS Sexual Encounter Profiles sexual event ) . Non-parametric statistical analysis collect data Comparing 3 group perform .</brief_summary>
	<brief_title>Safety Clinical Effectiveness 2 Lower Dose Combined PDE5i 's v . Single Maximal Dose PDE5i</brief_title>
	<detailed_description>A prospective , randomize , 3-arm parallel trial 45 male ED never expose PDE5i therapy ( naïve patient ) enrol . Recruitment perform via advertisement offer newly diagnose naïve ED patient visit clinic participate study . In group , every patient receive three treatment regime ( Viagra®50mg &amp; Levitra®10mg , Viagra®100mg , Levitra®20mg ) , different sequence administration , follow : Group 1 ) 15 naïve patient start Viagra®100mg , continue Levitra®20mg end study combine Viagra®50mg &amp; Levitra®10mg . Group 2 ) 15 naïve patient start combine Viagra®50mg &amp; Levitra®10mg , continue Levitra®20mg end study Viagra®100mg . Group 3 ) 15 naïve patient start Levitra®20mg , continue Viagra®100mg end study combine Viagra®50mg &amp; Levitra®10mg . Inclusion criterion : - Relationship partner least 3 month - Age range 35-65 year old - Sexually active , ( minimal frequency one sexual encounter per 2 week ) - IIEF ED domain score 22 . Exclusion criterion : - Subjects premature ejaculation main sexual complaint . - Subjects severe cardiovascular disease past 6 month , include cardiac failure , myocardial infarction , unstable angina , stroke transient ischemic attack , symptomatic clinically significant cardiac arrhythmia include atrial fibrillation , - Subjects Contraindications PDE5i therapy . Namely patient receive treatment nitrate base medication patient various reason take PDE5 inhibitor ( severe hepatic diseases- cirrhosis ALT ( Alanine aminotransferase ) &gt; 2x upper limit normal ) , renal impairment ( creatinine clearance &gt; 30ml/min ) know hereditary degenerative retinal disorder retinitis pigmentosa . , - Concomitant treatment potent CYP3A4 CYP2C9 inhibitor ( e.g protease inhibitor ritonavir saquinavir , ketoconazole , itrakonazole , miconazole , nefazodone , claritromycin , troleandomycin , erythromycin cimetidine ) - Subjects mentally unfit study . SAFETY &amp; ELIGIBILITY VISIT . After thorough explanation nature study protocol understand signing informed consent form . In visit , subject start study measure basic blood pressure level pulse rate . Under supervision subject take combine half dose suggest . Blood pressure monitor pulse rate every half- hour clinic perform 4 hour ( accord pharmacokinetic property medication ) . Any recording 20 mmhg baseline exclude subject study . If significant effect blood pressure note , subject eligible inclusion study , invite FIRST visit 7 day later . ( washout period one week sufficient eliminate effect one-time dosing combine half dose treatment ) . Each include patient come 6 visit respond follow pre-set sexual function satisfaction questionnaire ( Hebrew validate ) : 1 . The full IIEF ( International Index Erectile Function ) standard Questionnaire 2 . The SEAR ( Self-Esteem And Relationship ) questionnaire 3 . QVS ( Quality Sexual Life ) questionnaire 4 . Quality erection questionnaire 5 . Grade erection scale At visit , documentation side-effects do physical examination ( blood pressure pulse rate ) do . A 24 hour mobile phone dedicate patient inquiry provide patient whole study . Visit 1 : The subject offer , random , 4 attempt home , either combination dose regime ( Viagra®50mg &amp; Levitra®10mg , 4 tablet ) 4 tablet Viagra®100mg single dose 4 tablet Levitra® 20 mg . The subject also receive 6 SEP ( Sexual Encounter Profile ) diaries fill home sexual attempt . After 4 attempt subject return visit 2 , respond questionnaire additional EDITS ( Erectile Dysfunction Inventory Treatment Satisfaction ) questionnaire . A new visit reschedule 2 week later allow washout period . At visit 3 receive 2nd regime 4 new SEP diary , 4 attempt return visit 4 , fill 4 questionnaire . Again , new visit reschedule 2 week later allow washout period . On visit 5 return receive third treatment regime . Again , receive 4 SEP diary fill sexual attempt home . At final visit ( visit 6 ) , addition 4 questionnaire , patient require respond preference questionnaire regard preferred regime . The approximate timeline performing study every patient 1/2 year recruitment . The estimated timeline completion study 16 month . *Only inclusion ** Washout period 2 week Non-parametric statistical analysis collect data questionnaire perform .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Relationship partner least 3 month Age ranging 3565 year old Sexually active , ( minimal frequency one sexual encounter per 2 week ) IIEF ED domain score 22 . Subjects premature ejaculation main sexual complaint . Subjects severe cardiovascular disease past 6 month , include cardiac failure , myocardial infarction , unstable angina , stroke transient ischemic attack , symptomatic clinically significant cardiac arrhythmia include atrial fibrillation , Subjects Contraindications PDE5i therapy . Namely patient receive treatment nitrate base medication patient various reason take PDE5 inhibitor ( severe hepatic disease cirrhosis ALT ( Alanine aminotransferase ) &gt; 2x upper limit normal ) , renal impairment ( creatinine clearance &gt; 30ml/min ) know hereditary degenerative retinal disorder retinitis pigmentosa . , Concomitant treatment potent CYP3A4 CYP2C9 inhibitor ( e.g protease inhibitor ritonavir saquinavir , ketoconazole , itrakonazole , miconazole , nefazodone , claritromycin , troleandomycin , erythromycin cimetidine ) Subjects mentally unfit study .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Erectile Dysfunction</keyword>
	<keyword>Treatment</keyword>
	<keyword>PDE5i</keyword>
</DOC>